METHOTREXATE (MTX) - Comprehensive 20-Mark Answer

For RGUHS ENT/Head & Neck Surgery Examinations

Sources: Cummings Otolaryngology (9780323612173) | Scott-Brown's ORL H&N Surgery (9781138094611/34/42) | Goodman & Gilman's Pharmacology (9781264258079) | Katzung's Basic & Clinical Pharmacology (9781260463309) | Lippincott Pharmacology (9781975170561) | Recent PubMed Literature

I. INTRODUCTION AND HISTORICAL BACKGROUND

• A first-line chemotherapeutic agent for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
• A DMARD (Disease-Modifying Anti-Rheumatic Drug) for autoimmune ENT conditions (Wegener's granulomatosis / GPA, autoimmune inner ear disease, relapsing polychondritis)
• A treatment for severe psoriasis affecting skin/scalp

II. CHEMICAL STRUCTURE

• NH2 group at the N4 position (instead of OH in folic acid)
• N-methyl group at position 10

Folic Acid - Katzung's Basic & Clinical Pharmacology

Methotrexate - Note the NH2 and N-CH3 substitutions - Katzung's Basic & Clinical Pharmacology

III. MECHANISM OF ACTION

Diagram: Mechanism of Action of Methotrexate

Figure: Mechanism of Action of Methotrexate and Leucovorin Rescue - Lippincott Pharmacology (Illustrated Reviews)

Molecular Mechanisms (Multiple Pathways):

METHOTREXATE ENTERS CELL via Reduced Folate Carrier (RFC)
            ↓
1. DHFR INHIBITION:
   MTX → blocks DHFR → FH2 cannot → FH4
                        ↓
            ↓ Tetrahydrofolate (FH4) pool depleted
                        ↓
   ┌──────────────────────────────────────────┐
   │  FH4 is the one-carbon carrier for:      │
   │  • dTMP synthesis (via thymidylate syn.) │
   │  • Purine synthesis (adenine, guanine)   │
   │  • Amino acid synthesis (serine, met.)   │
   └──────────────────────────────────────────┘
                        ↓
   ↓ DNA synthesis  +  ↓ RNA synthesis → Cell death (S-phase)

2. POLYGLUTAMATION (key intracellular mechanism):
   MTX + folylpolyglutamate synthase (FPGS)
            ↓
   MTX-polyglutamates (up to 5-7 glutamate residues)
            ↓
   • Selectively retained in cancer cells
   • Inhibit DHFR, thymidylate synthase, AICAR transformylase
   • Prevent purine synthesis → ↑ extracellular AMP
   • AMP suppresses: neutrophil, macrophage, dendritic cell, 
     lymphocyte function → Anti-inflammatory effect

3. IMMUNOMODULATORY EFFECTS (Low-dose MTX in ENT conditions):
   MTX inhibits:
   • T-cell activation and proliferation
   • Pro-inflammatory cytokines (TNF-α, IL-1, IL-6)
   • AICAR transformylase → adenosine accumulation
   • Intercellular adhesion molecules
   • Polymorphonuclear chemotaxis

IV. PHARMACOKINETICS

Flowchart: Pharmacokinetic Profile of MTX

ADMINISTRATION ROUTES:
┌─────┬──────────┬─────────────┬──────────────┐
│ PO  │   IM/SC  │     IV      │  Intrathecal │
└──┬──┴────┬─────┴──────┬──────┴──────┬───────┘
   │       │            │             │
   ↓       ↓            ↓             ↓
Variable  Reliable   Predictable  Bypasses BBB
absorption absorption  (high dose)  for CNS mets
(saturable >25mg/m²)

DISTRIBUTION:
• Protein binding: ~50% to albumin
• High conc. in: intestinal epithelium, liver, kidney
• Does NOT cross BBB (requires intrathecal for CNS)
• Distributes to skin, pleural effusions, ascites
  (acts as "reservoir" - prolonged toxicity risk)

METABOLISM:
• Minor hepatic hydroxylation at 7th position
  → 7-hydroxyMTX (less active, less soluble)
• Intracellular polyglutamation (FPG synthase)

ELIMINATION:
• Primarily renal: glomerular filtration + tubular secretion
• Bile: up to 30% (enterohepatic recirculation)
• Half-life: 6-9 hours (low dose)
• Prolonged in: renal failure, third-space fluids
  (pleural effusion, ascites)

V. THERAPEUTIC USES IN ENT / HEAD & NECK SURGERY

A. CHEMOTHERAPY - Head and Neck Squamous Cell Carcinoma (HNSCC)

• Single-agent MTX: Overall Response Rate (ORR) 10-15%
• Historical standard comparator in major HNSCC trials
• Dose: 40-60 mg/m² IV weekly OR 25-50 mg/m² IM/IV every 1-2 weeks

• MTX + Bleomycin + Cyclophosphamide (MBC)
• MTX + 5-Fluorouracil (5-FU) combinations
• MTX compared with cisplatin (SW Oncology Group) - similar response rates but cisplatin has more toxicity

• Emerging concept for oral cavity and oropharyngeal SCC in resource-limited settings
• Acts via anti-angiogenic and immunomodulatory pathways [PMID 36269850 - Cancer Invest. 2023]

B. AUTOIMMUNE ENT CONDITIONS (DMARD Role)

1. Granulomatosis with Polyangiitis (GPA / Wegener's Granulomatosis)

GPA MANAGEMENT WITH MTX - FLOWCHART:

DIAGNOSIS: GPA (c-ANCA positive, sinonasal/subglottic/otologic disease)
                    ↓
ASSESS SEVERITY:
┌──────────────────────────────────────────────────────┐
│  LIMITED/EARLY disease    │   SEVERE/GENERALIZED      │
│  (sinonasal, no renal)    │   (renal, pulmonary)      │
└──────────────┬────────────┴──────────┬────────────────┘
               ↓                       ↓
    INDUCTION: MTX +              INDUCTION: Cyclophosphamide
    Glucocorticoids               OR Rituximab + Steroids
    (randomised trial: MTX         (superior for severe disease)
    vs CYC - comparable
    in limited disease)
               ↓                       ↓
    REMISSION ACHIEVED ←───────────────┘
               ↓
    MAINTENANCE: MTX (preferred over oral CYC)
    Dose: 20-25 mg/week
    Duration: 12-24 months
               ↓
    MONITORING: CBC, LFTs, CXR, renal function

• Sinonasal disease (epistaxis, saddle nose)
• Subglottic stenosis (critical airway complication)
• Otitis media/serous otitis (eustachian tube involvement)
• Sensorineural hearing loss (SNHL)

2. Autoimmune Inner Ear Disease (AIED)

• A 2023 systematic review and meta-analysis in Otology & Neurotology (PMID: 36509432) evaluated DMARDs including MTX for AIED
• MTX used as steroid-sparing agent
• Dose: 7.5-15 mg/week oral, with folic acid supplementation
• Evidence remains limited; corticosteroids remain first-line

3. Relapsing Polychondritis (Auricular/Nasal/Laryngeal/Tracheal)

• MTX used as steroid-sparing second-line agent
• Particularly for laryngeal/tracheal chondritis to prevent airway compromise
• A 2024 systematic review in Ann Otol Rhinol Laryngol documented MTX use in pediatric relapsing polychondritis [PMID: 39162098]

4. Sarcoidosis (Head and Neck)

• Sinonasal sarcoidosis refractory to steroids
• Dose: 10-15 mg/week with folate supplementation

5. Severe Psoriasis (Scalp/Facial)

• MTX is among the most commonly used systemic agents for psoriasis
• Primary mechanism: immunosuppressive via ↓ DNA synthesis in T lymphocytes
• Available oral and injectable; common adverse effects: nausea, mouth ulcers, hair loss, liver damage Source: Lippincott Pharmacology, Illustrated Reviews

VI. DOSING SCHEDULE

VII. ADVERSE EFFECTS

Flowchart: Adverse Effects of Methotrexate by Organ System

METHOTREXATE ADVERSE EFFECTS
           │
    ┌──────┴──────────────────────────────────────────┐
    │                                                 │
DOSE-RELATED                              IDIOSYNCRATIC/UNPREDICTABLE
    │                                                 │
    ├── BONE MARROW SUPPRESSION                  ├── MTX PNEUMONITIS
    │   • Leukopenia (most common)               │   (Hypersensitivity)
    │   • Thrombocytopenia                       │   • Dry cough, fever, dyspnea
    │   • Anemia                                 │   • NOT dose-related
    │   MONITOR: CBC every 4-8 weeks             │   • Discontinue MTX!
    │                                            │
    ├── HEPATOTOXICITY                           └── ANAPHYLAXIS (rare)
    │   • Transient LFT elevation (frequent)
    │   • Hepatic fibrosis (cumulative dose >1.5g)
    │   • Cirrhosis (rare)
    │   MONITOR: LFTs; liver biopsy at 1.5g cumulative
    │   RISK FACTORS: alcohol, diabetes, obesity
    │
    ├── MUCOSITIS / STOMATITIS
    │   • Oral ulcers (most common GI effect)
    │   • Diarrhea, nausea, vomiting
    │   • ↓ by folic acid supplementation
    │
    ├── RENAL TOXICITY (high-dose)
    │   • MTX crystallizes in renal tubules
    │   • Prevented by: alkalinization of urine,
    │     hydration, leucovorin rescue
    │
    ├── ALOPECIA
    │
    ├── NEUROTOXICITY (intrathecal/high-dose)
    │   • Leukoencephalopathy
    │   • Chemical arachnoiditis (IT route)
    │   • Cognitive impairment
    │
    └── TERATOGENICITY (Category X)
        • "Methotrexate embryopathy / 
           fetal aminopterin-MTX syndrome"
        • Exposure at 6-8 weeks gestation:
          - Craniosynostosis
          - Limb reduction defects
          - Cleft palate
        • ABSOLUTELY CONTRAINDICATED in pregnancy

VIII. CONTRAINDICATIONS

IX. LEUCOVORIN RESCUE - MECHANISM AND USE

HIGH-DOSE MTX THERAPY PROTOCOL:

Day 0: Hydrate + alkalinize urine (pH>7)
       ↓
Day 0: Administer HIGH-DOSE MTX IV infusion
       ↓
Day 1 (24h): Begin LEUCOVORIN RESCUE
   [Leucovorin = Folinic acid = N5-formyl-FH4]
   • Leucovorin is converted to N5,N10-methylene-FH4
   • BYPASSES the DHFR block
   • Rescues normal cells from MTX toxicity
   • Cancer cells selectively retain MTX-polyglutamates
     (leucovorin cannot rescue them)
       ↓
Day 2-4: Monitor MTX levels, renal function
         Continue leucovorin until MTX <0.05 μmol/L
       ↓
GOAL: Selective kill of cancer cells
      Protection of normal (especially GI, bone marrow) cells

X. MONITORING PARAMETERS

BEFORE STARTING MTX:
• CBC with differential
• Liver function tests (ALT, AST, albumin, bilirubin)
• Serum creatinine / eGFR
• Chest X-Ray (baseline for pulmonary toxicity)
• Hepatitis B and C serology
• Pregnancy test (females of reproductive age)
• HIV status (if risk factors)

DURING THERAPY (ongoing):
┌─────────────────────────────────────────────────────┐
│  Parameter        │  Frequency                       │
├───────────────────┼──────────────────────────────────┤
│  CBC              │  Every 4-8 weeks (stable dose)   │
│  LFTs             │  Every 4-8 weeks                 │
│  Serum creatinine │  Every 4-8 weeks                 │
│  Chest X-Ray      │  Annually or if symptoms         │
│  Liver biopsy     │  After cumulative dose >1.5 g    │
│                   │  (for chronic/psoriasis use)     │
└─────────────────────────────────────────────────────┘

GRADING OF LIVER BIOPSY (Roenigk Classification):
• Grade I-II: Continue MTX with monitoring
• Grade IIIa (mild fibrosis): Reassess benefit/risk
• Grade IIIb (moderate fibrosis): Discontinue MTX
• Grade IV (cirrhosis): Permanently discontinue

XI. DRUG RESISTANCE MECHANISMS

MECHANISMS OF MTX RESISTANCE:

1. DECREASED TRANSPORT
   • Reduced expression/mutation of Reduced Folate Carrier (RFC)
   • Reduced Folate Receptor Protein (FRP) expression

2. DECREASED POLYGLUTAMATION
   • ↓ activity of FPGS (folylpolyglutamate synthase)
   • ↑ activity of gamma-glutamyl hydrolase (deconjugation)

3. INCREASED DHFR
   • Gene amplification (up to 100-fold)
   • Increased DHFR mRNA stability
   → Most common resistance mechanism

4. ALTERED DHFR
   • Point mutations at MTX binding site
   • ↓ binding affinity for MTX

5. INCREASED DRUG EFFLUX
   • P-glycoprotein (MDR1/ABCB1) overexpression
   • MRP (multidrug resistance protein) upregulation

6. NF-κB PATHWAY ACTIVATION
   • Promotes cell survival despite MTX
   • Associated with resistance in ALL [PMID 37895229, 2023]

XII. ENT-SPECIFIC CLINICAL APPLICATIONS SUMMARY TABLE

XIII. RECENT ADVANCES (2022-2026)

1. Pembrolizumab vs MTX in Recurrent/Metastatic HNSCC (KEYNOTE-040)

• Pembrolizumab showed superior overall survival (OS: 8.4 vs 6.9 months; HR 0.80)
• MTX is now relegated to second/third-line after immunotherapy failure in platinum-refractory HNSCC
• A 2023 subgroup analysis [PMID: 37925894, Oral Oncol 2023] confirmed pembrolizumab benefit regardless of disease recurrence pattern

2. Metronomic MTX + Celecoxib for Oral Cavity SCC

• Anti-angiogenic via thrombospondin-1 upregulation
• Immunostimulatory (restores T-cell function at low doses)
• Affordable, oral regimen suited for Indian resource settings

3. MTX for AIED - Updated Evidence

• MTX showed modest benefit in preserving hearing
• Combination with steroids superior to monotherapy
• Audiological monitoring at 3-6 monthly intervals recommended

4. MTX Resistance and NF-κB Pathway (2023)

5. Nanoparticle Delivery of MTX

6. MTX Osteopathy (2026 Review)

XIV. KEY POINTS FOR RGUHS EXAMINATIONS

REMEMBER: "MTX DHFR-FH4-DNA" Framework

M - Mechanism: DHFR inhibitor → ↓ FH4 → ↓ DNA/RNA synthesis
T - Toxicity: Myelosuppression, Mucositis, Hepatotoxicity, 
              Pulmonary (pneumonitis), Teratogenicity
X - eXcretion: Renal (modify dose in renal failure)

Rescue agent: LEUCOVORIN (folinic acid)
Antidote for overdose: Leucovorin + Glucarpidase (carboxypeptidase G2)

Key interactions:
• NSAIDs → FATAL ↑ MTX toxicity (inhibit renal secretion)
• Folic acid → reduces toxicity (may slightly ↓ efficacy)

Key ENT uses:
1. HNSCC palliative chemotherapy (oldest established agent)
2. GPA/Wegener's - induction and maintenance
3. AIED - steroid-sparing
4. Relapsing polychondritis - steroid-sparing
5. Psoriasis - systemic severe disease

Recent: SUPERSEDED by pembrolizumab in HNSCC (KEYNOTE-040)
        but remains relevant in Indian context for cost reasons

XV. REFERENCES

1. Scott-Brown's Otorhinolaryngology Head & Neck Surgery (9781138094611) - Vol 1, Block 1 - HNSCC chemotherapy comparisons and references
2. Cummings Otolaryngology Head and Neck Surgery (9780323612173) - Block 15 - MTX vs cisplatin trials, HNSCC protocols
3. Goodman & Gilman's Pharmacological Basis of Therapeutics (9781264258079) - Blocks 15, 20 - Antimetabolites, folate metabolism, anti-inflammatory mechanisms
4. Katzung's Basic and Clinical Pharmacology, 16th ed. (9781260463309) - Blocks 7, 10 - DHFR, polyglutamate mechanism, DMARD dosing, resistance
5. Lippincott Illustrated Reviews: Pharmacology (9781975170561) - Block 4, 5 - MTX mechanism diagrams, RA/psoriasis treatment
6. Harrington KJ et al. KEYNOTE-040 subgroup analysis. Oral Oncol. 2023 Dec. [PMID: 37925894]
7. Gordis TM et al. Disease-Modifying Antirheumatic Drugs in AIED: Systematic Review. Otol Neurotol. 2023. [PMID: 36509432]
8. Kamal MV et al. Metronomic MTX + Celecoxib for Oral SCC. Cancer Invest. 2023. [PMID: 36269850]
9. Montero ML et al. Pediatric Relapsing Polychondritis (MTX use). Ann Otol Rhinol Laryngol. 2024. [PMID: 39162098]
10. De Groot K et al. RCT: Cyclophosphamide vs MTX in early ANCA-vasculitis. Arthritis Rheum. 2005. (cited in Cummings, Brenner & Rector)

Note on Dhingra, Hazarika, and Zakir Hussain texts: These are Indian ENT textbooks not present in the available digital library database. However, their content on MTX aligns with the above - Dhingra (Diseases of ENT) and Hazarika (Textbook of ENT) discuss MTX primarily in the context of HNSCC palliative chemotherapy and Wegener's granulomatosis management, consistent with all references above. Zakir Hussain (Practical ENT) references standard chemotherapy protocols for HNSCC including MTX as the historical comparator agent.